Clinical trials: Chronic Inflammatory Disease
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
- Trial name
- NCT01625182
- Testing
- Fingolimod
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.
- Trial name
- NCT02955355
- Testing
- HYQVIA
- Where
- 35 sites in United States, Argentina and 16 more
- Volunteers
- 85 people
- Sponsor
- Baxalta now part of Shire
End Stage Renal Disease
HeRO Vascular Access Device Post Market Procedural Survey Protocol
Post market observational survey of a vascular access device for access-challenged patients. Data collection efforts focused on patient medical and access history and implant procedure results.
- Trial name
- PPS (NCT00889291)
- Volunteers
- 77 people
- Sponsor
- Merit Medical Systems, Inc.
Ulcer
Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
- Trial name
- NCT00450216
- Testing
- Ibuprofen/famotidine, Ibuprofen
- Volunteers
- 906 people
- Sponsor
- Amgen
Polymyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids…
- Trial name
- NCT01801917
- Testing
- BAF312
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Migraine Disorders
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Chronic Migraine (CM), or 15 or more migraine headaches per month, is common in tertiary headache care and is associated with a number of deleterious outcomes, especially higher disability and poorer quality of life, relative to…
- Trial name
- NCT01435941
- Testing
- Non-steroidal anti-inflammatory drug (NSAID), Triptan
- Volunteers
- 11,249 people
- Sponsor
- GlaxoSmithKline
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Chronic Inflammatory Disease
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001…
- Trial name
- NCT05323110
- Testing
- CBS001
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Capella Bioscience Ltd
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Pelvic Pain
A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease
The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease
- Trial name
- NCT05970783
- Testing
- Jincaopian Tablets
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and…
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Trial name
- NCT07264426
- Testing
- Efgartigimod PH20 SC
- Where
- 23 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- argenx
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Small Bowel Disease, Crohn's Disease
PillCam SBC System Functionality in Established and Suspected IBD Patients
This clinical study is designed to evaluate the PillCam SBC system performance in 50 established or suspected inflammatory bowel disease (IBD) patients by visualizing and assessing their small and large bowel.
- Trial name
- PIANO (NCT02742714)
- Testing
- PillCam SBC system
- Where
- 5 sites in Israel, Italy and 1 more
- Volunteers
- 54 people
- Sponsor
- Medtronic - MITG
Atopic Dermatitis
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
- Trial name
- ADSTEM Inj (NCT07377838)
- Testing
- ADSTEM Inj.
- Volunteers
- 286 people
- Sponsor
- EHL Bio Co., Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP.
- Trial name
- NCT04825626
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD)
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)
This is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic Obstructive Pulmonary Disease).
- Trial name
- NCT00144859
- Testing
- SB681323
- Where
- 17 sites in Denmark, Finland and 3 more
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.
- Trial name
- PRISM (NCT02293460)
- Testing
- I10E
- Where
- 33 sites in France, Italy and 4 more
- Volunteers
- 44 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR)…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis
- Trial name
- NCT05940922
- Testing
- No intervention. Retrospective observation only.
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- RwHealth
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.
- Trial name
- VITALIZE (NCT06290141)
- Testing
- riliprubart, IVIg
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 160 people
- Sponsor
- Sanofi